- Angiomyolipoma
- Kidney cancer
- Prostate cancer
- Tuberous sclerosis
Naomi B. Haas, MD
Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West
Penn Medicine Provider
About me
- Director, Prostate and Kidney Cancer Program
- Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
My education and training
- Medical School: Northeastern Ohio University - College of Medicine
- Residency: Abington Memorial Hospital
- Fellowship: Fox Chase Cancer Center
Spoken languages
English
English
Reviews
740 reviews
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
Insurance accepted
Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.
- Aetna Advantra Cares D-SNP
- Aetna Advantra Credit Value
- Aetna Advantra Eagle HMO
- Aetna Advantra Eagle POS
- Aetna Advantra Premier Plus PPO
- Aetna Advantra Value
- Aetna Advantra Value Plus
- Aetna APCN Plus (Multi-Tier)
- Aetna Better Health Kids (CHIP) - DH Only
- Aetna Flexible Five
- Aetna Freedom Core
- Aetna Gold
- Aetna HMO
- Aetna Philly Prime
- Aetna POS
- Aetna PPO APCN
- Aetna Premier
- Aetna Premier Plus
- Aetna Savings Plus
- Aetna Signature Administrators
- Aetna Student Health Plan PPO
- Aetna Upfront Advantage
- First Health HMO
- First Health POS
- First Health PPO
- Meritain - Aramark (Other)
- Meritain - Aramark (Pennsylvania Premier Medical Plan)
- Americhealth Caritas of PA VIP - LGH Only
- Amerihealth Caritas (Transplant patients only)
- Amerihealth Caritas of PA - LGH Only
- Centivo EPO
- Cigna Healthcare EPO
- Cigna Healthcare HMO
- Cigna Healthcare POS
- Cigna Healthcare PPO
- Claim Watcher (Homestead/ INDECs) Open Access
- Clover Health Choice
- Clover Health Choice Value PPO
- Clover Health Classic HMO
- Clover Health Value
Locations
Penn Medicine hospital privileges
- Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
- Penn Presbyterian Medical Center: On the medical staff, but does not have privileges to treat patients in the hospital.
Qualifications and experience
- Medical Oncology, 1995
- Internal Medicine, 1988
- American Association for Cancer Research, International
- American Society of Clinical Oncology, International
- Eastern Cooperative Oncology Group (Melanoma Committee, Genitourinary Committee), National
- ECOG/ACRIN, National
- ECOG-ACRIN, National
- NCCN Kidney Cancer Panel, National
- NCI Genitourinary Steering Committee, National
- Penn Genitourinary and Urologic Cancer Program
Treatments and conditions
Research
Publications
Mamtani R, Pfanzelter N, Haynes K, Finkelman BS, Wang X, Keefe SM, Haas NB, Vaughn DJ, Lewis JD. Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas. , Diabetes Care, 37(7): 2014 ,1910-7
Haas NB, Quirt I, Hotte S, McWhirter E, Polintan R, Litwin S, Adams PD, McBryan T, Wang L, Martin LP, vonMehren M, Alpaugh RK, Zweibel J, Oza A. Phase II trial of Vorinostat in advanced melanoma , Invest New Drugs, 32(3): 2014,526-34
Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. , J Clin Oncol, 31(4): 2013,412-9
Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma , J Clin Oncol, 31(2): 2013,181-6
Jang JW, Hwang WT, Guzzo TJ, Wein AJ, Haas NB, Both S, Vapiwala N. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA. , Int J Radiat Oncol Biol Phys, 83(5): 2012,1493-9
Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. , Med Oncol. (Northwood, London, England), 29(2): 2012,761-7
Swisher-McClure S, Pollack CE, Christodouleas JP, Guzzo TJ, Haas NB, Vapiwala N, Bekelman JE. Variation in use of androgen suppression with external-beam radiotherapy for nonmetastatic prostate cancer. , Int J Radiat Oncol Biol Phys., 83(1): 2012,8-15
Swisher-McClure S, Pollack CE, Christodouleas JP, Guzzo TJ, Haas NB, Vapiwala N, Bekelman JE. Variation in use of androgen suppression with external-beam radiotherapy for nonmetastatic prostate cancer. , Int J Radiat Oncol Biol Phys., 83(1): 2012,8-15
Yeboa DN, Guzzo T, Mitra N, Christodouleas JP, Haas NB, Vapiwala N, Armstrong K, Bekelman JE. Prostate-specific antigen surveillance among men with clinically localized prostate cancer who do not receive initial treatment. , Urology.: 2011
Yeboa DN, Guzzo T, Mitra N, Christodouleas JP, Haas NB, Vapiwala N, Armstrong K, Bekelman JE. Prostate-specific antigen surveillance among men with clinically localized prostate cancer who do not receive initial treatment. , Urology., 78(5): 2011,1107-13